for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Puma Biotechnology Inc

PBYI.N

Latest Trade

11.72USD

Change

0.63(+5.68%)

Volume

2,492

Today's Range

11.37

 - 

11.73

52 Week Range

5.51

 - 

14.97

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
11.09
Open
11.39
Volume
2,492
3M AVG Volume
12.10
Today's High
11.73
Today's Low
11.37
52 Week High
14.97
52 Week Low
5.51
Shares Out (MIL)
39.76
Market Cap (MIL)
466.41
Forward P/E
-8.50
Dividend (Yield %)
--

Next Event

Q4 2020 Puma Biotechnology Inc Earnings Release

Latest Developments

More

Puma Biotechnology Reports Third Quarter 2020 Financial Results

Puma Biotechnology Reports Q2 Adjusted Non-GAAP Earnings Per Share Of $0.35

Acentrus Specialty Says Finalized Agreement With Puma Biotechnology

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Puma Biotechnology Inc

Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib, oral), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment of patients with HER2 positive metastatic breast cancer. It focuses on developing neratinib as an intravenously administered agent. The intravenous version of neratinib resulted in exposure levels of neratinib in pre-clinical models. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors.

Industry

Biotechnology & Drugs

Contact Info

10880 Wilshire Blvd Ste 2150

LOS ANGELES, CA

90024-4106

United States

+1.424.2486500

https://www.pumabiotechnology.com/

Executive Leadership

Alan H. Auerbach

Chairman of the Board, President, Chief Executive Officer

Maximo F. Nougues

Chief Financial Officer

Douglas Hunt

Senior Vice President, Regulatory Affairs, Medical Writing and Project Management

Richard Paul Bryce

Chief Medical and Scientific Officer

Jay M. Moyes

Lead Independent Director

Key Stats

3.30 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.3K

2019

0.3K

2020(E)

0.2K
EPS (USD)

2017

-7.850

2018

-2.990

2019

-1.950

2020(E)

-1.380
Price To Earnings (TTM)
--
Price To Sales (TTM)
1.98
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-39.14
Return on Equity (TTM)
-22.77

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up